NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis $5.21 -0.08 (-1.51%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.22 +0.00 (+0.10%) As of 09/5/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evoke Pharma Stock (NASDAQ:EVOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evoke Pharma alerts:Sign Up Key Stats Today's Range$5.16▼$5.2650-Day Range$2.60▼$6.9952-Week Range$1.94▼$12.32Volume9,684 shsAverage Volume436,877 shsMarket Capitalization$8.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. Read More Evoke Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreEVOK MarketRank™: Evoke Pharma scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Evoke Pharma. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evoke Pharma is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evoke Pharma is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvoke Pharma has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Evoke Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.25% of the float of Evoke Pharma has been sold short.Short Interest Ratio / Days to CoverEvoke Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evoke Pharma has recently increased by 18.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvoke Pharma does not currently pay a dividend.Dividend GrowthEvoke Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.25% of the float of Evoke Pharma has been sold short.Short Interest Ratio / Days to CoverEvoke Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evoke Pharma has recently increased by 18.60%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Evoke Pharma this week, compared to 1 article on an average week.Search Interest4 people have searched for EVOK on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evoke Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.29% of the stock of Evoke Pharma is held by insiders.Read more about Evoke Pharma's insider trading history. Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVOK Stock News HeadlinesContrasting Evoke Pharma (NASDAQ:EVOK) and Supernus Pharmaceuticals (NASDAQ:SUPN)September 6 at 3:49 AM | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Stock Rating Upgraded by Wall Street ZenAugust 30, 2025 | americanbankingnews.comTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.September 7 at 2:00 AM | Crypto 101 Media (Ad)Evoke Pharma, EVERSANA expand GIMOTI access with Omnicell relationshipAugust 26, 2025 | msn.comEvoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell RelationshipAugust 26, 2025 | globenewswire.comEvoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange BookAugust 21, 2025 | globenewswire.comEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 17, 2025 | finance.yahoo.comEvoke Pharma Reports Strong Q2 2025 Sales GrowthAugust 15, 2025 | msn.comSee More Headlines EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed this year? Evoke Pharma's stock was trading at $4.42 at the beginning of the year. Since then, EVOK stock has increased by 17.9% and is now trading at $5.21. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) posted its quarterly earnings results on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.32. The specialty pharmaceutical company had revenue of $3.75 million for the quarter, compared to the consensus estimate of $3.80 million. Evoke Pharma had a negative net margin of 42.07% and a negative trailing twelve-month return on equity of 99.48%. When did Evoke Pharma's stock split? Shares of Evoke Pharma reverse split before market open on Thursday, August 1st 2024.The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/14/2025Today9/07/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVOK CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year Founded2007Profitability EPS (Trailing Twelve Months)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.35 million Net Margins-42.07% Pretax Margin-42.07% Return on Equity-99.48% Return on Assets-33.58% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio1.32 Sales & Book Value Annual Sales$10.25 million Price / Sales0.79 Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book1.10Miscellaneous Outstanding Shares1,560,000Free Float1,523,000Market Cap$8.13 million OptionableNot Optionable Beta-0.13 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:EVOK) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVOK Stock Alerts